jueves, 24 de noviembre de 2016

Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. - PubMed - NCBI

Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. - PubMed - NCBI

 2015 Aug;22(8):630-8. doi: 10.1111/jvh.12412.

Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.

Abstract

Recent advances in the treatment of hepatitis C virus (HCV) infection have led to the availability of both highly efficacious interferon-containing and interferon-sparing regimens. However, the use of such therapies faces restrictions due to high costs. For patients who are medically eligible to receive interferon, the choice between the two will likely be impacted by preferences surrounding interferon, severity of disease, coverage policies and out-of-pocket costs. We developed a decision model to quantify the trade-offs between immediate, interferon-containing therapy and delayed, interferon-free therapy for patients with chronic, genotype 1 HCV infection. We projected the quality-adjusted life expectancy stratified by the presence or absence of cirrhosis for four strategies: (i) no treatment; (ii) immediate, one-time treatment with an interferon-containing regimen; (iii) immediate treatment as above with the opportunity for retreatment in patients who fail to achieve sustained virologic response with interferon-free therapy in 1 year; and (iv) delayed therapy with interferon-free therapy in 1 year. When compared to one-time immediate treatment with the interferon-containing regimen, delayed treatment with the interferon-free regimen in 1 year resulted in longer life expectancy, with a 0.2 quality-adjusted life year (QALY) increase in noncirrhotic patients, and a 1.1 QALY increase in patients with cirrhosis. This superiority in health benefits was lost when wait time for interferon-free therapy was greater than 3-3.2 years. In this modelling analysis, interferon-free therapy resulted in superior health benefits compared to immediate therapy with interferon until wait time exceeded 3-3.2 years. Such data can inform decision-making regarding treatment initiation for HCV as healthcare financing evolves.

KEYWORDS:

HCV; decision analysis; interferon sparing; treatment timing

Comment in

PMID:
 
26135026
 
PMCID:
 
PMC4515086
 
DOI:
 
10.1111/jvh.12412
[PubMed - indexed for MEDLINE] 
Free PMC Article